Who are SHR-A1811 for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab + Relatlimab, Nivolumab-relatlimab FDC, MEDI4736 + Tremelimumab, Durvalumab +Tremelimumab, Cadonilimab (AK104), APVO101.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shr-a1811-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SHR-A1811 for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-A1811 for Injection (SHR-A1811 for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody; dual checkpoint inhibitor. Area: Oncology.

phase 3 Bispecific monoclonal antibody; dual checkpoint inhibitor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SHR-A1811 for Injection (SHR-A1811 for Injection) — Suzhou Suncadia Biopharmaceuticals Co., Ltd.. SHR-A1811 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SHR-A1811 for Injection TARGET	SHR-A1811 for Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
Nivolumab-relatlimab FDC	Nivolumab-relatlimab FDC	Bristol-Myers Squibb	phase 3	Dual checkpoint inhibitor (PD-1/LAG-3)	PD-1 and LAG-3
MEDI4736 + Tremelimumab	MEDI4736 + Tremelimumab	AstraZeneca	phase 3	Dual checkpoint inhibitor (PD-L1 inhibitor + CTLA-4 inhibitor)	PD-L1 and CTLA-4
Durvalumab +Tremelimumab	Durvalumab +Tremelimumab	AstraZeneca	phase 3	Dual checkpoint inhibitor combination (PD-L1 inhibitor + CTLA-4 inhibitor)	PD-L1 and CTLA-4
Cadonilimab (AK104)	Cadonilimab (AK104)	Guangxi Medical University	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor	PD-L1 and TIM-3
APVO101	APVO101	Medexus Pharma, Inc.	phase 3	Dual checkpoint inhibitor	PD-1 and CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody; dual checkpoint inhibitor class)

Guangxi Medical University · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR-A1811 for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/shr-a1811-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing